Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons.
Neuropharmacol. 149, 13-26 (2019)
Pathological aggregates of alpha-synuclein are the common hallmarks of synucleinopathies, including Parkinson's disease. There is currently no disease-modifying therapy approved for neurodegenerative synucleinopathies. The induction of macroautophagy by small compounds may be a strategy to reduce the cellular alpha-synuclein burden and to confer neuroprotection. Therefore, in the present study, we investigated a broad spectrum of druggable molecular signaling pathways reported to induce macroautophagy in human cells and compared their protective efficacy against alpha-synuclein-induced toxicity in cultured human postmitotic dopaminergic neurons. Several compounds affecting different pathways were able to activate macroautophagy. All compounds that activated autophagy also protected against alpha-synuclein-induced toxicity. The compounds with the lowest effective concentrations were PI-103, L-690,330, and NF 449, making them particularly interesting for further investigations, including in vivo models. Our findings demonstrate that activation of macroautophagy, as a neuroprotective approach in synucleinopathies, is accessible to pharmacotherapy. Moreover, pharmacological activation of macroautophagy via diverse signaling pathways is effective to protect human dopaminergic neurons against alpha-synuclein-induced toxicity.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
4.367
1.067
5
9
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Chaperone-mediated Autophagy; Parkinsons-disease; Cell-death; Inhibition; Neurodegeneration; Monophosphatase; Carbamazepine; Degradation; Clearance; Apoptosis
Sprache
englisch
Veröffentlichungsjahr
2019
HGF-Berichtsjahr
2019
ISSN (print) / ISBN
0028-3908
e-ISSN
1873-7064
Zeitschrift
Neuropharmacology
Quellenangaben
Band: 149,
Seiten: 13-26
Verlag
Elsevier
Verlagsort
Orlando, Fla. [u.a.]
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Developmental Genetics (IDG)
POF Topic(s)
30204 - Cell Programming and Repair
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-500500-001
WOS ID
WOS:000462802900002
Scopus ID
85061656436
PubMed ID
30731136
Erfassungsdatum
2019-02-28